Molecular neurobiology and promising new treatment in depression

International Journal of Molecular Sciences

Volumn 17, Issue 3, 2016, Pages

  Jeon, Sang Won ^a   Kim, Yong Ku ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Antidepressant; BDNF; Depression; Endocrine; Gene; Immune; MTOR; Neural plasticity; Neurobiology

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; FLUOXETINE; MIFEPRISTONE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CIRCADIAN RHYTHM; DEPRESSION; FOOD INTAKE; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; MOLECULAR BIOLOGY; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROBIOLOGY; SIGNAL TRANSDUCTION; BRAIN; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANTIDEPRESSIVE AGENTS; BRAIN; CIRCADIAN RHYTHM; CLINICAL TRIALS AS TOPIC; DEPRESSION; HUMANS; MAP KINASE SIGNALING SYSTEM; NEURONAL PLASTICITY; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84961251622     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17030381     Document Type: Article

References (99)

1. Keller, M.B.; Hirschfeld, R.M.; Demyttenaere, K.; Baldwin, D.S. Optimizing outcomes in depression: Focus on antidepressant compliance. Int. Clin. Psychopharmacol. 2002,17, 265-271. [CrossRef] [PubMed]
2. Racagni, G.; Popoli, M., Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin. Neurosci. 2008,10, 385-400. [PubMed]
3. Zarate, C.A., Jr.; Singh, J.B.; Carlson, P.J.; Brutsche, N.E.; Ameli, R.; Luckenbaugh, D.A.; Charney, D.S.; Manji, H.K. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen Psychiatry 2006, 63, 856-864. [CrossRef] [PubMed]
4. Price, J.L.; Drevets, W.C. Neural circuits underlying the pathophysiology of mood disorders. Trends Cognit. Sci. 2012,16, 61-71. [CrossRef] [PubMed]
5. Jacobson, L.; Sapolsky, R. The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr. Rev. 1991,12,118-134. [CrossRef] [PubMed]
6. Bremner, J.D.; Narayan, M.; Anderson, E.R.; Staib, L.H.; Miller, H.L.; Charney, D.S. Hippocampal volume reduction in major depression. Am. J. Psychiatry 2000,157,115-118. [CrossRef] [PubMed]
7. Murray, E.A.; Wise, S.P.; Drevets, W.C. Localization of dysfunction in major depressive disorder: Prefrontal cortex and amygdala. Biol. Psychiatry 2011, 69, e43-e54. [CrossRef] [PubMed]
8. Chen, C.H.; Suckling, J.; Ooi, C.; Fu, C.H.; Williams, S.C.; Walsh, N.D.; Mitterschiffthaler, M.T.; Pich, E.M.; Bullmore, E. Functional coupling of the amygdala in depressed patients treated with antidepressant medication. Neuropsychopharmacology 2008, 33,1909-1918. [CrossRef] [PubMed]
9. Burke, J.; McQuoid, D.R.; Payne, M.E.; Steffens, D.C.; Krishnan, R.R.; Taylor, W.D. Amygdala volume in late-life depression: Relationship with age of onset. Am. J. Geriatr. Psychiatry 2011,19, 771-776. [CrossRef] [PubMed]
10. Ongur, D.; Bechtholt, A.J.; Carlezon, W.A., Jr.; Cohen, B.M. Glial abnormalities in mood disorders. Harv. Rev. Psychiatry 2014, 22, 334-337. [CrossRef] [PubMed]
11. Nestler, E.J.; Carlezon, W.A., Jr. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 2006, 59, 1151-1159. [CrossRef] [PubMed]
12. Willner, P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int. Clin. Psychopharmacol. 1997,12, S7-S14. [CrossRef] [PubMed]
13. Schildkraut, J.J. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am. J. Psychiatry 1965,122, 509-522. [CrossRef] [PubMed]
14. Sulser, F.; Vetulani, J.; Mobley, P.L. Mode of action of antidepressant drugs. Biochem. Pharmacol. 1978, 27, 257-261. [CrossRef]
15. Vetulani, J.; Sulser, F. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 1975, 257, 495-496. [CrossRef] [PubMed]
16. Peroutka, S.J.; Snyder, S.H. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 1980, 210, 88-90. [CrossRef] [PubMed]
17. Riva, M.A.; Creese, I. Reevaluation of the regulation of beta-adrenergic receptor binding by desipramine treatment. Mol. Pharmacol. 1989, 36, 211-218. [PubMed]
18. Blier, P.; de Montigny, C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 1994,15, 220-226. [CrossRef]
19. Duman, R.S.; Malberg, J.; Thome, J. Neural plasticity to stress and antidepressant treatment. Biol. Psychiatry 1999, 46,1181-1191. [CrossRef]
20. Duman, R.S.; Malberg, J.; Nakagawa, S.; D'Sa, C. Neuronal plasticity and survival in mood disorders. Biol. Psychiatry 2000, 48, 732-739. [CrossRef]
21. Yu, H.; Chen, Z.Y. The role of BDNF in depression on the basis of its location in the neural circuitry. Acta Pharmacol. Sin. 2011, 32,3-11. [CrossRef] [PubMed]
22. Lee, B.H.; Kim, Y.K. The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig. 2010, 7, 231-235. [CrossRef] [PubMed]
23. Castren, E.; Rantamaki, T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev. Neurobiol. 2010, 70, 289-297. [CrossRef] [PubMed]
24. Groves, J.O. Is it time to reassess the BDNF hypothesis of depression? Mol. Psychiatry 2007,12,1079-1088. [CrossRef] [PubMed]
25. Krishnan, V.; Nestler, E.J. The molecular neurobiology of depression. Nature 2008, 455, 894-902. [CrossRef] [PubMed]
26. Eisch, A.J.; Bolanos, C.A.; de Wit, J.; Simonak, R.D.; Pudiak, C.M.; Barrot, M.; Verhaagen, J.; Nestler, E.J. Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: A role in depression. Biol. Psychiatry 2003, 54, 994-1005. [CrossRef] [PubMed]
27. Numakawa, T.; Suzuki, S.; Kumamaru, E.; Adachi, N.; Richards, M.; Kunugi, H. BDNF function and intracellular signaling in neurons. Histol. Histopathol. 2010, 25, 237-258. [PubMed]
28. Belujon, P.; Grace, A.A. Hippocampus, amygdala, and stress: Interacting systems that affect susceptibility to addiction. Ann. NY Acad. Sci. 2011,1216,114-121. [CrossRef] [PubMed]
29. Anacker, C.; Cattaneo, A.; Luoni, A.; Musaelyan, K.; Zunszain, P.A.; Milanesi, E.; Rybka, J.; Berry, A.; Cirulli, F.; Thuret, S.; et al. Glucocorticoid-related molecular signaling pathways regulating hippocampal neurogenesis. Neuropsychopharmacology 2013, 38, 872-883. [CrossRef] [PubMed]
30. Maric, N.P.; Adzic, M. Pharmacological modulation of HPA axis in depression—New avenues for potential therapeutic benefits. Psychiatr. Danub. 2013,25, 299-305. [PubMed]
31. Zorrilla, E.P.; Koob, G.F. Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov. Today 2010,15, 371-383. [CrossRef] [PubMed]
32. Kehne, J.H.; Cain, C.K. Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: Evidence from animal models. Pharmacol. Ther. 2010,128, 460-487. [CrossRef] [PubMed]
33. Zobel, A.W.; Nickel, T.; Kunzel, H.E.; Ackl, N.; Sonntag, A.; Ising, M.; Holsboer, F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated. J. Psychiatr. Res. 2000, 34,171-181. [CrossRef]
34. Zorrilla, E.P.; Koob, G.F. The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig. Drugs 2004,13, 799-828. [CrossRef] [PubMed]
35. Kormos, V.; Gaszner, B. Role of neuropeptides in anxiety, stress, and depression: From animals to humans. Neuropeptides 2013, 47, 401-419. [CrossRef] [PubMed]
36. Wulsin, A.C.; Herman, J.P.; Solomon, M.B. Mifepristone decreases depression-like behavior and modulates neuroendocrine and central hypothalamic-pituitary-adrenocortical axis responsiveness to stress. Psychoneuroendocrinology 2010, 35,1100-1112. [CrossRef] [PubMed]
37. Mondelli, V.; Dazzan, P.; Hepgul, N.; Di Forti, M.; Aas, M.; D'Albenzio, A.; Di Nicola, M.; Fisher, H.; Handley, R.; Marques, T.R.; et al. Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: The role of stress and of antipsychotic treatment. Schizophr. Res. 2010,116, 234-242. [CrossRef] [PubMed]
38. Adell, A., Antidepressant properties of substance P antagonists: Relationship to monoaminergic mechanisms? Curr. Drug Targets CNS Neurol. Disord. 2004, 3,113-121. [CrossRef] [PubMed]
39. Ebner, K.; Rupniak, N.M.; Saria, A.; Singewald, N. Substance P in the medial amygdala: Emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc. Natl. Acad. Sci. USA 2004,101, 4280-4285. [CrossRef] [PubMed]
40. Ryckmans, T.; Balancon, L.; Berton, O.; Genicot, C.; Lamberty, Y.; Lallemand, B.; Pasau, P.; Pirlot, N.; Quere, L.; Talaga, P. First dual NK1 antagonists-serotonin reuptake inhibitors: Synthesis and SAR of a new class of potential antidepressants. Bioorg. Med. Chem. Lett. 2002,12, 261-264. [CrossRef]
41. Morcuende, S.; Gadd, C.A.; Peters, M.; Moss, A.; Harris, E.A.; Sheasby, A.; Fisher, A.S.; De Felipe, C.; Mantyh, P.W.; Rupniak, N.M.; et al. Increased neurogenesis and brain-derived neurotrophic factor in neurokinin-1 receptor gene knockout mice. Eur. J. Neurosci. 2003,18,1828-1836. [CrossRef] [PubMed]
42. Slusarczyk, J.; Trojan, E.; Chwastek, J.; Glombik, K.; Basta-Kaim, A. A potential contribution of chemokine network dysfunction to the depressive disorders. Curr. Neuropharmacol. 2016.
43. Uddin, M.; Koenen, K.C.; Aiello, A.E.; Wildman, D.E.; de los Santos, R.; Galea, S. Epigenetic and inflammatory marker profiles associated with depression in a community-based epidemiologic sample. Psychol. Med. 2011, 41, 997-1007. [CrossRef] [PubMed]
44. Musselman, D.L.; Lawson, D.H.; Gumnick, J.F.; Manatunga, A.K.; Penna, S.; Goodkin, R.S.; Greiner, K.; Nemeroff, C.B.; Miller, A.H. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 2001, 344, 961-966. [CrossRef] [PubMed]
45. Capuron, L.; Gumnick, J.F.; Musselman, D.L.; Lawson, D.H.; Reemsnyder, A.; Nemeroff, C.B.; Miller, A.H. Neurobehavioral effects of interferon-a in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26, 643-652. [CrossRef]
46. Khairova, R.A.; Machado-Vieira, R.; Du, J.; Manji, H.K. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int. J. Neuropsychopharmacol. 2009,12, 561-578. [CrossRef] [PubMed]
47. Maes, M.; Meltzer, H.Y.; Bosmans, E.; Bergmans, R.; Vandoolaeghe, E.; Ranjan, R.; Desnyder, R. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 1995, 34, 301-309. [CrossRef]
48. Sluzewska, A.; Rybakowski, J.K.; Laciak, M.; Mackiewicz, A.; Sobieska, M.; Wiktorowicz, K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. NY Acad. Sci. 1995, 762, 474-476. [CrossRef] [PubMed]
49. Frommberger, U.H.; Bauer, J.; Haselbauer, P.; Fraulin, A.; Riemann, D.; Berger, M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: Comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurosci. 1997, 247, 228-233. [CrossRef] [PubMed]
50. Basterzi, A.D.; Aydemir, C.; Kisa, C.; Aksaray, S.; Tuzer, V.; Yazici, K.; Goka, E. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum. Psychopharmacol. 2005, 20,473-476. [CrossRef] [PubMed]
51. Maes, M.; Bosmans, E.; De Jongh, R.; Kenis, G.; Vandoolaeghe, E.; Neels, H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997, 9, 853-858. [CrossRef] [PubMed]
52. Hinze-Selch, D.; Schuld, A.; Kraus, T.; Kuhn, M.; Uhr, M.; Haack, M.; Pollmacher, T. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-a and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 2000, 23,13-19. [CrossRef]
53. Himmerich, H.; Binder, E.B.; Kunzel, H.E.; Schuld, A.; Lucae, S.; Uhr, M.; Pollmacher, T.; Holsboer, F.; Ising, M. Successful antidepressant therapy restores the disturbed interplay between TNF-a system and HPA axis. Biol. Psychiatry 2006, 60, 882-888. [CrossRef] [PubMed]
54. Tuglu, C.; Kara, S.H.; Caliyurt, O.; Vardar, E.; Abay, E. Increased serum tumor necrosis factor-a levels and treatment response in major depressive disorder. Psychopharmacology 2003,170, 429-433. [CrossRef] [PubMed]
55. Kagaya, A.; Kugaya, A.; Takebayashi, M.; Fukue-Saeki, M.; Saeki, T.; Yamawaki, S.; Uchitomi, Y. Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor a of depressed patients in Japan. Neuropsychobiology 2001, 43, 59-62. [CrossRef] [PubMed]
56. Mikova, O.; Yakimova, R.; Bosmans, E.; Kenis, G.; Maes, M. Increased serum tumor necrosis factor a concentrations in major depression and multiple sclerosis. Eur. Neuropsychopharmacol. 2001, 11, 203-208. [CrossRef]
57. Kim, Y.K.; Suh, I.B.; Kim, H.; Han, C.S.; Lim, C.S.; Choi, S.H.; Licinio, J. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: Effects of psychotropic drugs. Mol. Psychiatry 2002, 7,1107-1114. [CrossRef] [PubMed]
58. Lee, K.M.; Kim, Y.K. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int. Immunopharmacol. 2006, 6,1298-1304. [CrossRef] [PubMed]
59. Sutcigil, L.; Oktenli, C.; Musabak, U.; Bozkurt, A.; Cansever, A.; Uzun, O.; Sanisoglu, S.Y.; Yesilova, Z.; Ozmenler, N.; Ozsahin, A.; et al. Pro- and anti-inflammatory cytokine balance in major depression: Effect of sertraline therapy. Clin. Dev. Immunol. 2007, 2007, 76396. [CrossRef] [PubMed]
60. Dowlati, Y.; Herrmann, N.; Swardfager, W.; Liu, H.; Sham, L.; Reim, E.K.; Lanctot, K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67, 446-457. [CrossRef] [PubMed]
61. Miller, G.E.; Cohen, S.; Ritchey, A.K. Chronic psychological stress and the regulation of pro-inflammatory cytokines: A glucocorticoid-resistance model. Health Psychol. 2002, 21, 531-541. [CrossRef] [PubMed]
62. Myint, A.M.; Kim, Y.K. Cytokine-serotonin interaction through IDO: A neurodegeneration hypothesis of depression. Med. Hypotheses 2003, 61, 519-525. [CrossRef]
63. Krishnadas, R.; Cavanagh, J. Depression: An inflammatory illness? J. Neurol. Neurosurg. Psychiatry 2012, 83, 495-502. [CrossRef] [PubMed]
64. Muller, N.; Schwarz, M.J.; Dehning, S.; Douhe, A.; Cerovecki, A.; Goldstein-Muller, B.; Spellmann, I.; Hetzel, G.; Maino, K.; Kleindienst, N.; et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 2006,11, 680-684. [CrossRef] [PubMed]
65. Nery, F.G.; Monkul, E.S.; Hatch, J.P.; Fonseca, M.; Zunta-Soares, G.B.; Frey, B.N.; Bowden, C.L.; Soares, J.C. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study. Hum. Psychopharmacol. 2008, 23, 87-94. [CrossRef] [PubMed]
66. Wang, Y.; Yang, F.; Liu, Y.F.; Gao, F.; Jiang, W. Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats. Neurosci. Lett. 2011, 499, 74-79. [CrossRef] [PubMed]
67. Lin, P.Y.; Mischoulon, D.; Freeman, M.P.; Matsuoka, Y.; Hibbeln, J.; Belmaker, R.H.; Su, K.P. Are w-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. Mol. Psychiatry 2012,17,1161-1163. [CrossRef] [PubMed]
68. Davies, N.M.; Kehoe, P.G.; Ben-Shlomo, Y.; Martin, R.M. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J. Alzheimers Dis. 2011, 26, 699-708. [PubMed]
69. Opmeer, E.M.; Kortekaas, R.; Aleman, A. Depression and the role of genes involved in dopamine metabolism and signalling. Prog. Neurobiol. 2010, 92,112-133. [CrossRef] [PubMed]
70. Lesch, K.P.; Bengel, D.; Heils, A.; Sabol, S.Z.; Greenberg, B.D.; Petri, S.; Benjamin, J.; Muller, C.R.; Hamer, D.H.; Murphy, D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274,1527-1531. [CrossRef] [PubMed]
71. Baca-Garcia, E.; Vaquero, C.; Diaz-Sastre, C.; Saiz-Ruiz, J.; Fernandez-Piqueras, J.; de Leon, J. A gender-specific association between the serotonin transporter gene and suicide attempts. Neuropsychopharmacology 2002,26, 692-695. [CrossRef]
72. Kendler, K.S.; Kuhn, J.W.; Prescott, C.A. Childhood sexual abuse, stressful life events and risk for major depression in women. Psychol. Med. 2004, 34,1475-1482. [CrossRef] [PubMed]
73. Zubenko, G.S.; Maher, B.; Hughes, H.B., 3rd; Zubenko, W.N.; Stiffler, J.S.; Kaplan, B.B.; Marazita, M.L. Genome-wide linkage survey for genetic loci that influence the development of depressive disorders in families with recurrent, early-onset, major depression. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003,123b, 1-18. [CrossRef] [PubMed]
74. Pifarre, P.; Garcia, A.; Mengod, G. Species differences in the localization of soluble guanylyl cyclase subunits in monkey and rat brain. J. Comp. Neurol. 2007, 500, 942-957. [CrossRef] [PubMed]
75. Nakagawa, S.; Kim, J.E.; Lee, R.; Malberg, J.E.; Chen, J.; Steffen, C.; Zhang, Y.J.; Nestler, E.J.; Duman, R.S. Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J. Neurosci. 2002,22, 3673-3682. [PubMed]
76. Woudstra, S.; Bochdanovits, Z.; van Tol, M.J.; Veltman, D.J.; Zitman, F.G.; van Buchem, M.A.; van der Wee, N.J.; Opmeer, E.M.; Demenescu, L.R.; Aleman, A.; et al. Piccolo genotype modulates neural correlates of emotion processing but not executive functioning. Transl. Psychiatry 2012, 2, e99. [CrossRef] [PubMed]
77. Anguelova, M.; Benkelfat, C.; Turecki, G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: I. Affective disorders. Mol. Psychiatry 2003, 8, 574-591. [CrossRef] [PubMed]
78. Elzinga, B.M.; Molendijk, M.L.; Oude Voshaar, R.C.; Bus, B.A.; Prickaerts, J.; Spinhoven, P.; Penninx, B.J. The impact of childhood abuse and recent stress on serum brain-derived neurotrophic factor and the moderating role of BDNF Val66Met. Psychopharmacology 2011, 214, 319-328. [CrossRef] [PubMed]
79. Roy, M.; David, N.; Cueva, M.; Giorgetti, M. A study of the involvement of melanin-concentrating hormone receptor 1 (MCHR1) in murine models of depression. Biol. Psychiatry 2007, 61,174-180. [CrossRef] [PubMed]
80. Ozsoy, S.; Besirli, A.; Abdulrezzak, U.; Basturk, M. Serum ghrelin and leptin levels in patients with depression and the effects of treatment. Psychiatry Investig. 2014,11,167-172. [CrossRef] [PubMed]
81. Jow, G.M.; Yang, T.T.; Chen, C.L. Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J. Affect. Disord. 2006, 90, 21-27. [CrossRef] [PubMed]
82. Westling, S.; Ahren, B.; Traskman-Bendz, L.; Westrin, A. Low CSF leptin in female suicide attempters with major depression. J. Affect. Disord. 2004, 81, 41-48. [CrossRef] [PubMed]
83. Gecici, O.; Kuloglu, M.; Atmaca, M.; Tezcan, A.E.; Tunckol, H.; Emul, H.M.; Ustundag, B. High serum leptin levels in depressive disorders with atypical features. Psychiatry Clin. Neurosci. 2005,59, 736-738. [CrossRef] [PubMed]
84. Luppino, F.S.; de Wit, L.M.; Bouvy, P.F.; Stijnen, T.; Cuijpers, P.; Penninx, B.W.; Zitman, F.G. Overweight, obesity, and depression: A systematic review and meta-analysis of longitudinal studies. Arch. Gen. Psychiatry 2010, 67, 220-229. [CrossRef] [PubMed]
85. Labruna, G.; Pasanisi, F.; Nardelli, C.; Caso, R.; Vitale, D.F.; Contaldo, F.; Sacchetti, L. High leptin/adiponectin ratio and serum triglycerides are associated with an “at-risk" phenotype in young severely obese patients. Obesity 2011,19,1492-1496. [CrossRef] [PubMed]
86. Grierson, A.B.; Hickie, I.B.; Naismith, S.L.; Hermens, D.F.; Scott, E.M.; Scott, J. Circadian rhythmicity in emerging mood disorders: State or trait marker? Int. J. Bipolar Disord. 2016, 4, 3. [CrossRef] [PubMed]
87. Pompili, M.; Serafini, G.; Innamorati, M.; Venturini, P.; Fusar-Poli, P.; Sher, L.; Amore, M.; Girardi, P. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review. World J. Biol. Psychiatry 2013,14, 412-431. [CrossRef] [PubMed]
88. Tuli, H.S.; Kashyap, D.; Sharma, A.K.; Sandhu, S.S. Molecular aspects of melatonin (MLT)-mediated therapeutic effects. Life Sci. 2015,135,147-157. [CrossRef] [PubMed]
89. Pringle, A.; Bogdanovskaya, M.; Waskett, P.; Zacharia, S.; Cowen, P.J.; Harmer, C.J. Does melatonin treatment change emotional processing? Implications for understanding the antidepressant mechanism of agomelatine. J. Psychopharmacol. 2015, 29,1129-1132. [CrossRef] [PubMed]
90. Liu, J.; Clough, S.J.; Hutchinson, A.J.; Adamah-Biassi, E.B.; Popovska-Gorevski, M.; Dubocovich, M.L. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu. Rev. Pharmacol. Toxicol. 2016,56, 361-383. [CrossRef] [PubMed]
91. Costa-Mattioli, M.; Sossin, W.S.; Klann, E.; Sonenberg, N. Translational control of long-lasting synaptic plasticity and memory. Neuron 2009, 61,10-26. [CrossRef] [PubMed]
92. Proud, C.G. Signalling to translation: How signal transduction pathways control the protein synthetic machinery. Biochem. J. 2007, 403, 217-234. [CrossRef] [PubMed]
93. Farber, N.B. The NMDA receptor hypofunction model of psychosis. Ann. NY Acad. Sci. 2003,1003,119-130. [CrossRef] [PubMed]
94. Thomas, D.M.; Kuhn, D.M. MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Res. 2005,1050,190-198. [CrossRef] [PubMed]
95. DiazGranados, N.; Ibrahim, L.A.; Brutsche, N.E.; Ameli, R.; Henter, I.D.; Luckenbaugh, D.A.; Machado-Vieira, R.; Zarate, C.A., Jr. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J. Clin. Psychiatry 2010, 71,1605-1611. [CrossRef] [PubMed]
96. Li, N.; Lee, B.; Liu, R.J.; Banasr, M.; Dwyer, J.M.; Iwata, M.; Li, X.Y.; Aghajanian, G.; Duman, R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329, 959-964. [CrossRef] [PubMed]
97. Autry, A.E.; Adachi, M.; Nosyreva, E.; Na, E.S.; Los, M.F.; Cheng, P.F.; Kavalali, E.T.; Monteggia, L.M. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475, 91-95. [CrossRef] [PubMed]
98. Li, N.; Liu, R.J.; Dwyer, J.M.; Banasr, M.; Lee, B.; Son, H.; Li, X.Y.; Aghajanian, G.; Duman, R.S. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 2011, 69, 754-761. [CrossRef] [PubMed]
99. Jernigan, C.S.; Goswami, D.B.; Austin, M.C.; Iyo, A.H.; Chandran, A.; Stockmeier, C.A.; Karolewicz, B. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35,1774-1779. [CrossRef] [PubMed]